PLETHICO

��Members of the Exchange are hereby notified that in terms of Regulation 22(6) of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Rule 21(2) b of Securities Contract (Regulations) Rules, 1957 , it has been decided to delist (withdraw the admission to dealings in) equity shares of the Plethico Pharmaceuticals Limited w.e.f. May 30, 2018 as per Chapter V of SEBI (Delisting of Equity Shares) Regulations, 2009.

Members of the Exchange are hereby informed that the Exchange on February 28, 2018 has issued public notice in the newspaper for�� proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

Plethico Pharmaceuticals Limited has informed the Exchange that the Company has received a resignation letter from the Director Ms Meena Matani.

Shashikant A. Patel has submitted to the Exchange vide letter dated April 07, 2016 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Plethico Pharmaceuticals Limited has informed the Exchange that With a view to address the delay in repayment of principal and interest on fixed deposits, service banking facilities, pay statutory dues and sustain its business operations, the Company has opted to adopt contract manufacturing model for its operation.

Plethico Pharmaceuticals Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2015.

Plethico Pharmaceuticals Limited has informed the Exchange that the Trading Window for the equity shares of the Company shall remain closed from March 9, 2016 to March 16, 2016 (both days inclusive) . lnter-alia to consider and approve the audited financial results for the quarter and year ended March 31, 2015.Accordingly, all the insiders and Designated Persons (including directors and employees) and others who have come in to the receipt of any insider information are hereby directed not to deal in shares of he Company during the period of closure of Trading Window as stated above.

Plethico Pharmaceuticals Limited has informed the Exchange regarding appointment and resignation of Whole Time Director and Reconstitution of the Committee.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the details of authorized Key Managerial Personnel for the purpose of determining materiality of an event or information and for the purpose of making disclosures to the Stock Exchanges.

Plethico Pharmaceuticals Limited has informed the Exchange about the Intimation of Appointment of Director and Rename and Reconstitution of the Committee

Plethico Pharmaceuticals Limited has informed the Exchange regarding the Outcome of the Extra Ordinary General Meeting of the Members of the Company held on December 29, 2015.

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of the notice published in the newspaper regarding Extra-Ordinary General Meeting of the members of the company to be held on December 29, 2015.

Plethico Pharmaceuticals Limited has informed the Exchange regarding Corporate Updates- 1. Acquisition of M/s Natrol Inc, USA by M/s. Aurobindo Pharma. 2.Merging of Administrative Office of the Company with the Registered Office Of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange regarding Postponement of Board Meeting Scheduled to be held on May 29, 2015 for the purpose of approval of Audited Financial Results of the Company for the Quarter and Year ended on March 31, 2015.

Plethico Pharmaceuticals Limited has informed the Exchange that pursuant to the Trading Window of the Company shall remain closed from May 22, 2015 to June 01, 2015 (both days inclusive) for designated employees for dealing in securities of the Company.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors at there meeting held on March 31, 2015, inter-alia, considered the following:- 1. Appointment of Mr. Deen Bandhu Roy, as an additional Director of the Company. 2. Appointment of Mrs. Meena Matani, as an additional Director of the Company. 3. Appointment of Ms. Anuradha Kumari, as an additional Director of the Company. 4.Acceptance of Resignation of Mr. Pramod K. Shrivastava, Director of the Company, effective from the conclusion of this meeting. 5. To file a application before the concerned authorities

Plethico Pharmaceuticals Limited has submitted to the exchange the consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Plethico Pharmaceuticals Limited has informed the Exchange regarding Shifting of Corporate Office of the Company from Sabnam House, Plot No.A-15/16, Central Cross Road-B, M.I.D.C Andheri (E), Mumbai - 400093 to Shop No: 262, Lower Ground Floor, Dreams the Mall, L B S Marg, Bhandup (W), Mumbai - 400078.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on February 14, 2015, inter-alia, considered the following :- 1. Acceptance of Resignation of Dr. G. N. Qazi, Independent Non-Executive Director of the Company, effective from the conclusion of this meeting. 2. Shifting of Corporate Office of the Company from Sabnam House, Plot No.A-15/16, Central Cross Road-B, M.I.D.C Andheri (E), Mumbai-400093 to Shop No: 262, Lower Ground Floor, Dreams the Mall, L B S Marg, Bhandup (W), Mumbai - 400078.

Plethico Pharmaceuticals Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Plethico Pharmaceuticals Limited has informed the Exchange that the Trading Window of the Company shall remain closed for the directors and designated employees covered under the Code for dealing in the securities of the Company from February 12, 2015 till twenty-four hours after making corporate announcement of the outcome of Board Meeting declaring Un-audited Financial Results for the quarter and nine months ended December 31, 2014 to the Stock Exchanges.

Plethico Pharmaceuticals Limited has submitted to the Exchange the revised details of voting results of the Annual General Meeting of the Company held on the December 26, 2014 along with Report of Scrutinizer pursuant to clause 35A of the Listing Agreement.

Plethico Pharmaceuticals Limited has submitted to the Exchange the details of voting results of the Annual General Meeting of the Company held on the December 26, 2014 along with Report of Scrutinizer pursuant to clause 35A of the Listing Agreement.

Plethico Pharmaceuticals Limited has informed the Exchange that the Register of Members & Share Transfer Books of the Company will remain closed from December 17, 2014 to December 19, 2014 (both days inclusive) for the purpose of Annual General Meeting (AGM) of the Company to be held on December 26, 2014.

Plethico Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Plethico Pharmaceuticals Limited has informed the Exchange that pursuant to the "Company's Code of Conduct for Prevention of Insider Trading", the Trading Window of the Company shall remain closed for the directors and designated employees covered under the Code for dealing in the securities of the Company from November 12, 2014 till twenty-four hours after making corporate announcement of the outcome of Board Meeting declaring Un-audited Financial Results for the second quarter and half year ended September 30, 2014 to the Stock Exchanges.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on September 09, 2014, inter-alia, decided to postpone its Annual General Meeting which was scheduled on September 29, 2014 and make an application to the Registrar of Companies, Madhya Pradesh for extension of time for a period of three months for holding the AGM.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of directors at their meeting held on August 13, 2014 inter-alia, considered the following:1) Fixing September 29, 2014 for holding the Annual General Meeting of the Members of the Company for the 15 months period ended March 31 ,2014 at the registered office of the company. 2) Acceptance of Resignation of Mr. Pranav Koshal, Independent Non- executive Director of the Company effective from the conclusion of this meeting.

Plethico Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-Jun-2014.

Price movement : Significant price movement has been observed in Plethico Pharmaceuticals Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Plethico Pharmaceuticals Limited has vide its letter inter-alia stated,"There is no event/information that have to be announced to the exchanges which may have any bearing on the operations/performance of the Company."

Plethico Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.

Plethico Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-dec-2013.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on January 24, 2014 has considered the following: (1) Extension of its current accounting/ financial year by a period of 3 (Three) months so as to align financial year of the Company in terms of provisions of Companies Act, 2013. As such, current accounting year shall be for a period of 15 (fifteen) months commencing from January 01, 2013 and ends on March 31, 2014. The subsequent accounting years, as such, shall commence from 1st April and end on 31st March every year.(2)

Plethico Pharmaceuticals Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-sep-2013.

Plethico Pharmaceuticals Limited has informed the Exchange that : (a) Mr. Amrish Kumar Chourasia, Company Secretary, ceased to be the Company Secretary of the Company, w.e.f. September 27, 2013, consequent to his resignation dated July 29, 2013; (b) Ms. Khushboo Kothari is appointed as the Company Secretary of the Company, w.e.f. September 27, 2013. Further, Ms. Khushboo Kothari, Company Secretary is appointed as the Compliance Officer of the Company, w.e.f. September 27, 2013.

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended June 30,2013.

Plethico Pharmaceuticals Limited has informed the Exchange with reference to the news item that was flashed on a leading financial news channel regarding the enquiry on the Company, the Company clarified to the Exchange that there is no basis to the rumor and the Company denies all alleged contents.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the details of Voting results at the Annual General Meeting of the Company held on June 28, 2013, under Clause 35A.

Plethico Pharmaceuticals Limited has informed the Exchange that the Company has fixed Book Closure from June 25, 2013 to June 28, 2013 (both days inclusive) for the purpose of Annual General Meeting.

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on June 01, 2013, inter-alia, has decided in-principle to issue bonus shares to the shareholders other than promoters/promoter group shareholders in the ratio of 1(one) Share for every 5 (Five) Shares held by them subject to necessary approval of SEBI for waiver of certain condition stipulated under SEBI ICDR Regulations and/or extension of time to comply with the Minimum Public Shareholding (MPS) requirements. The issue of Bonus share will be implemented only on receipt of

Plethico Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 14, 2013, inter-alia, considered the following :(1) Fixing the June 28, 2013 for holding of the 20th Annual General Meeting of the members of the Company for the accounting year ended December 31, 2012. (2) Approval of text of advertisement for acceptance and renewal of deposits in accordance with the provisions of the Companies (Acceptance of Deposits) Rules, 1975, framed under section 58A of the Companies Act, 1956.

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended March 31,2013.

Plethico Pharmaceuticals Limited has informed the Exchange regarding the Outcome of an Extra-Ordinary General Meeting of the Company held on April 05, 2013 under Clause 35A of the Listing Agreement.

Shashikant Patel has submitted to the Exchange, vide letter dated March 26, 2013 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Shashikant Patel has submitted to the Exchange vide letter dated March 15, 2013 a copy of Disclosure under Regulation 31(1) & 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Plethico Pharmaceuticals Limited has submitted to the Exchange a copy of Notice of an Extra-ordinary General Meeting of the Members of the Company to be held on April 05, 2013.

Shashikant Patel has submitted to the Exchange vide letter dated March 05, 2013 a copy of Disclosure in terms of Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Plethico Pharmaceuticals Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2012.

Shashikant Patel has submitted to the Exchange, vide letter dated December 10, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with disclosure pursuant to Regulation 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Shashikant Patel has submitted to the Exchange, vide letter dated November 20, 2012, a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.